…
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Statera Biopharma Inc is a publicly traded company on the OTC Pink market that identifies as a biopharmaceutical firm; public disclosures about its pipeline, commercial products and financials are limited. Long-term value may depend on successful clinical development, regulatory approvals, strategic partnerships and access to capital, so investors may benefit if those execution milestones are achieved.
Primary risks include low liquidity typical of Pink‑sheet listings, execution and clinical/regulatory risk for development-stage programs, and the potential for financing-related dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -101.88M | -101.88M | -12.09M | -3.22M | -3.61M |
| Minority interest | - | 0.02M | - | 0.21M | - |
| Net income | -174.41M | -101.85M | -13.22M | -3.35M | -3.61M |
| Selling general administrative | 18.41M | 19.91M | 5.24M | 2.23M | 2.32M |
| Selling and marketing expenses | 0.08M | - | 0.00M | - | - |
| Gross profit | -0.49M | -0.49M | 11.54M | 15.14M | 1.91M |
| Reconciled depreciation | - | 0.26M | 0.00M | 0.00M | - |
| Ebit | 38.68M | -31.24M | -10.50M | -2.81M | -0.99M |
| Ebitda | 38.93M | -30.49M | -10.50M | -2.81M | -4.80M |
| Depreciation and amortization | 0.26M | - | 0.00M | -0.29M | - |
| Non operating income net other | - | - | 2.93M | 1.37M | 0.84M |
| Operating income | 38.68M | -30.74M | -10.50M | -2.81M | -4.80M |
| Other operating expenses | 29.32M | - | 10.50M | 2.81M | 5.94M |
| Interest expense | 4.56M | - | 1.13M | 0.12M | 0.00M |
| Net interest income | - | -4.56M | -1.13M | -0.12M | - |
| Income tax expense | 72.53M | - | 1.13M | 0.12M | 0.29M |
| Total revenue | 1.49M | 0.00M | 41.55M | 47.07M | 7.59M |
| Total operating expenses | 28.83M | 30.74M | 10.50M | 2.81M | 5.94M |
| Cost of revenue | 0.49M | 0.49M | 30.01M | 31.93M | 5.68M |
| Total other income expense net | -140.55M | -66.57M | -1.59M | -0.41M | 1.19M |
| Discontinued operations | - | 0.00M | 0.00M | 0.00M | -0.90M |
| Net income from continuing ops | - | -101.88M | -6.76M | -5.51M | -1.66M |
| Net income applicable to common shares | - | -101.85M | -6.76M | -5.71M | -2.92M |
| Preferred stock and other adjustments | - | - | - | - | 0.36M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 21.17M | 21.17M | 1.04M | 0.00M | 4.53M |
| Intangible assets | 1.58M | 1.58M | - | - | - |
| Other current assets | 0.02M | 0.85M | 0.33M | 0.05M | 0.10M |
| Total liab | 22.68M | 22.68M | 4.69M | 4.21M | 0.92M |
| Total stockholder equity | -1.57M | -1.57M | -3.66M | -4.21M | -1.45M |
| Deferred long term liab | - | - | 0.16M | - | 0.16M |
| Other current liab | 2.08M | 0.70M | 0.14M | 1.26M | 0.77M |
| Common stock | 0.18M | 0.18M | 0.02M | 0.02M | 0.06M |
| Capital stock | - | 0.18M | 0.03M | 0.02M | - |
| Retained earnings | -129.48M | -129.48M | -27.63M | -15.54M | -164.06M |
| Good will | 9.27M | 9.27M | 4.45M | 4.45M | - |
| Other assets | - | 5.00M | - | -0.03M | - |
| Cash | 1.84M | 1.84M | 0.59M | 0.00M | 3.62M |
| Total current liabilities | 11.25M | 11.25M | 4.62M | 4.21M | 0.91M |
| Current deferred revenue | 0.37M | - | -0.14M | -1.26M | - |
| Net debt | 14.42M | 13.36M | 1.41M | 1.80M | -3.62M |
| Short term debt | 4.83M | - | 1.93M | 1.80M | 0.20M |
| Short long term debt | - | 4.58M | 1.90M | 1.80M | - |
| Short long term debt total | 16.26M | - | 2.00M | 1.80M | - |
| Other stockholder equity | 127.74M | -0.01M | 24.63M | 11.31M | 163.16M |
| Property plant equipment | - | 1.17M | 0.11M | 60.36M | 0.55M |
| Total current assets | 4.16M | 4.16M | 0.93M | 0.00M | 4.48M |
| Long term investments | - | - | 11.90M | 10.52M | 9.98M |
| Net tangible assets | - | -12.42M | 57.58M | 63.39M | 11.72M |
| Short term investments | 0.13M | 0.13M | 0.32M | 0.45M | 0.50M |
| Net receivables | 0.35M | 0.35M | 0.01M | 0.38M | 0.25M |
| Long term debt | - | 10.62M | 0.68M | - | - |
| Inventory | 1.81M | - | -0.01M | -0.42M | 0.07M |
| Accounts payable | 3.96M | 3.96M | 2.69M | 2.41M | 0.14M |
| Accumulated other comprehensive income | -0.01M | - | -0.69M | -0.57M | -0.61M |
| Common stock total equity | - | - | 0.02M | 0.02M | 0.01M |
| Retained earnings total equity | - | - | -29.39M | -22.63M | -5.42M |
| Treasury stock | - | - | - | - | -0.96M |
| Non currrent assets other | 5.00M | 5.00M | 53.15M | 0.03M | 0.06M |
| Non current assets total | 17.01M | 17.01M | 0.11M | 0.03M | 0.06M |
| Capital lease obligations | - | 1.06M | 0.10M | - | - |
| Long term debt total | - | - | 0.68M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | 13.46M | -0.01M | 0.00M | - |
| Change to liabilities | - | 1.24M | -0.45M | 1.93M | -5.06M |
| Total cashflows from investing activities | - | 13.46M | -0.26M | -3.24M | 9.86M |
| Net borrowings | - | 13.97M | -3.19M | 1.94M | 1.02M |
| Total cash from financing activities | 20.99M | 20.99M | 5.68M | 0.23M | 0.06M |
| Change to operating activities | - | 0.66M | -0.33M | 0.41M | -0.41M |
| Net income | -101.88M | -101.85M | -12.09M | -3.22M | -3.71M |
| Change in cash | 6.25M | 6.25M | 0.59M | -0.01M | -0.61M |
| Begin period cash flow | 0.59M | 0.59M | 0.00M | 0.01M | 4.23M |
| End period cash flow | 6.84M | 6.84M | 0.59M | 0.00M | 3.62M |
| Total cash from operating activities | -28.19M | -28.19M | -5.08M | -0.24M | -4.61M |
| Issuance of capital stock | - | 7.34M | 5.75M | 0.00M | - |
| Depreciation | 0.26M | 0.26M | 0.00M | 0.01M | 0.02M |
| Other cashflows from investing activities | - | - | -0.06M | 0.05M | 0.01M |
| Change to inventory | -1.00M | -0.13M | -0.05M | -0.03M | 0.12M |
| Change to account receivables | -0.35M | -0.42M | 0.38M | -0.07M | 0.43M |
| Sale purchase of stock | - | - | - | - | -0.04M |
| Other cashflows from financing activities | -0.13M | -0.33M | 4.34M | 0.16M | 0.06M |
| Change to netincome | - | 71.92M | 0.08M | -1.29M | -3.34M |
| Capital expenditures | 0.18M | 0.18M | 0.01M | 2.12M | 0.26M |
| Change receivables | - | - | -0.33M | -0.77M | 2.65M |
| Cash flows other operating | - | - | -0.20M | 0.51M | 3.63M |
| Exchange rate changes | - | - | - | - | -0.17M |
| Cash and cash equivalents changes | - | - | -2.12M | 2.81M | -0.17M |
| Change in working capital | 1.07M | 1.07M | -0.05M | 1.11M | 0.11M |
| Stock based compensation | 6.06M | 6.06M | 2.70M | - | - |
| Other non cash items | -1.30M | -1.30M | 7.06M | 1.86M | -1.03M |
| Free cash flow | -28.38M | -28.38M | -5.09M | -0.24M | -4.61M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STAB Statera Biopharma Inc |
- -% |
0.00 | - | - | 0.00 | 0.16 | 314.42 | -0.46 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
4333 Corbett Drive,, Fort Collins, CO, United States, 80525
888 613 8802
46
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Kevin Handley | CEO, Pres & Chairman | 1971 |
| Mr. Christopher Zosh | Exec. VP of Fin., Interim Principal Financial Officer & Interim Principal Accounting Officer | 1976 |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer | 1960 |
| Todd Headley | Exec. VP of Corp. Devel. | NA |
| George Wagner | Exec. VP of Regulatory Affairs | NA |
| Dr. Blake Hawley D.V.M., M.B.A. | Executive Chairman | 1965 |
| Mr. Christopher Zosh | Executive VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer | 1976 |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.